Interpace Biosciences (OTCMKTS:IDXG) Releases Quarterly Earnings Results

Interpace Biosciences (OTCMKTS:IDXG) released its quarterly earnings data on Tuesday. The business services provider reported $0.03 earnings per share (EPS) for the quarter, Zacks reports. Interpace Biosciences had a net margin of 63.46% and a return on equity of 493.02%.

Interpace Biosciences Price Performance

Shares of IDXG stock traded down $0.07 on Tuesday, hitting $2.00. The company’s stock had a trading volume of 158 shares, compared to its average volume of 8,454. Interpace Biosciences has a fifty-two week low of $0.70 and a fifty-two week high of $2.40. The firm’s fifty day moving average price is $1.90 and its 200-day moving average price is $1.52. The stock has a market capitalization of $8.86 million, a price-to-earnings ratio of -100.00 and a beta of 0.65.

About Interpace Biosciences

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.